SUSTAINED VIRAL RESPONSE AND SAFETY OF MK-7009 IN CIRRHOTIC TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE 1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON AND RIBAVIRIN TREATMENT

被引：1
|
作者：
Rodriguez-Torres, M. [1 ]
Stoehr, A. [2 ]
Gane, E. [3 ]
Serfaty, L. [4 ]
Lawitz, E. [5 ]
Bourque, M. [6 ,7 ]
Bhanja, S. [6 ,7 ]
Barnard, R. [6 ,7 ]
Hwang, P. [6 ,7 ]
Mobashery, N. [6 ,7 ]
机构：
[1] Fdn Invest Diego, San Juan, PR USA
[2] IFI Inst Interdisziplinare Med, Hamburg, Germany
[3] Auckland Clin Studies Ltd, Auckland, New Zealand
[4] Univ Paris 06, Serv Hepatol, Paris, France
[5] Alamo Med Res, San Antonio, TX USA
[6] Merck Sharp & Dohme Corp, West Point, PA USA
[7] Merck Sharp & Dohme Corp, N Wales, PA USA
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60108-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
106
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [41] EARLY VIRAL RESPONSE (EVR) RATES IN TREATMENT-NAiVE PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION TREATED WITH MK-7009, A NOVEL NS3/4A PROTEASE INHIBITOR, IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS
    Manns, Michael P.
    Gane, Edward J.
    Rodriguez-Torres, Maribel
    Stoehr, Albrecht D.
    Yeh, Chau-Ting
    Marcellin, Patrick
    Wiedmann, Richard T.
    Hwang, Peggy
    Barnard, Richard J.
    Quirk, Erin
    Kartsonis, Nicholas A.
    Lee, Andrew W.
    HEPATOLOGY, 2009, 50 (04) : 332A - 333A
  • [42] HIGH SUSTAINED VIRAL RESPONSE AT 12-AND 24-WEEK FOLLOW-UP OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS
    Manns, M.
    Vierling, J. M.
    Bacon, B. R.
    Marcellin, P.
    Caro, L.
    Gress, J.
    Gilbert, C.
    Cooreman, M. P.
    Robertson, M.
    Hwang, P.
    Wahl, J.
    Mobashery, N.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S30 - S30
  • [43] High Rates of SVR in Treatment-Experienced Patients with Genotype 1 HCV Infection and Cirrhosis After Treatment with Ledipasvir/Sofosbuvir and Vedroprevir with or Without Ribavirin for 8 weeks
    Lawitz, Eric
    Poordad, Fred
    Hyland, Robert H.
    Liu, Lin
    Dvory, Hadas S.
    Pang, Phillip S.
    Brainard, Diana M.
    Gutierrez, Julio A.
    HEPATOLOGY, 2015, 62 : 337A - 337A
  • [44] Muscle adiposity influences viral response to pegylated interferon plus ribavirin treatment in patients with genotype 1 chronic hepatitis C
    Okada, Michiaki
    Mizuta, Toshihiko
    Kitajima, Yoichiro
    Kawaguchi, Yasunori
    Iwane, Shinji
    Ide, Yasushi
    Eguchi, Yuichiro
    Anzai, Keizo
    Ozaki, Iwata
    HEPATOLOGY, 2013, 58 : 1152A - 1152A
  • [45] Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin
    Agarwal, Kosh
    Schultz, Michael
    Pianko, Stephen
    Bank, Leslie
    Collier, Jane
    George, Jacob
    Priest, Matthew
    Ryder, Stephen D.
    Burman, Blaire E.
    Cheent, Kuldeep
    Cramp, Matthew
    Forton, Daniel M.
    Leggett, Barbara A.
    MacQuillan, Gerry C.
    Ramji, Alnoor
    Richardson, Paul
    Ryan, Michael J.
    Stace, Nigel
    Zekry, Amany
    Zogg, Donald L.
    Barnes, Eleanor
    Brainard, Diana M.
    Massetto, Benedetta
    Chen, Frances
    McHutchison, John G.
    Subramanian, Mani
    Yoshida, Eric M.
    Foster, Graham R.
    HEPATOLOGY, 2016, 64 : 455A - 456A
  • [46] Hispanic patients with genotype 2 or 3 chronic hepatitis C have lower rates of sustained virologic response to treatment with pegylated interferon and ribavirin
    Douglass, Jeff
    Qualls, Clifford
    Wiggins, Charles
    Dunkelberg, Jeff
    Arora, Sanjeev
    GASTROENTEROLOGY, 2006, 130 (04) : A770 - A770
  • [47] The efficacy and safety of sofosbuvir plus ribavirin with or without peg-interferon in treatment of naive and experienced Vietnamese patients with chronic genotype 1 and 6 HCV infection
    Thu Thuy Pham Thi
    Tan Dat Ho
    HEPATOLOGY, 2016, 64 : 954A - 954A
  • [48] Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?
    Silva, Carla
    Ianna, Elizabeth
    Jones, Tracey
    Davis, Joshua S.
    HEPATOLOGY, 2015, 62 (02) : 660 - 661
  • [49] SOFOSBUVIR plus PEGINTERFERON/RIBAVIRIN FOR 12 WEEKS VS SOFOSBUVIR plus RIBAVIRIN FOR 16 OR 24 WEEKS IN GENOTYPE 3 HCV INFECTED PATIENTS AND TREATMENT-EXPERIENCED CIRRHOTIC PATIENTS WITH GENOTYPE 2 HCV: THE BOSON STUDY
    Foster, G. R.
    Pianko, S.
    Cooper, C.
    Brown, A.
    Forton, D.
    Nahass, R. G.
    George, J.
    Barnes, E.
    Brainard, D. M.
    Massetto, B.
    Lin, M.
    McHutchison, J. G.
    Subramanian, G. M.
    Agarwal, K.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S259 - S260
  • [50] Treatment with Pegylated Interferon alpha 2b and Ribavirin (rebetol) produces significant sustained virologic response rates in HCV infected patients who failed prior therapy.
    Gaglio, PJ
    Zimmerman, D
    Choi, J
    Heller, L
    Brown, RS
    HEPATOLOGY, 2003, 38 (04) : 318A - 318A
12345